Y. Kim

发表

Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer.

L. Neckers, J. Trepel, J. Gestwicki, 2018, Cancer research.

Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas.

P. Choyke, J. Doroshow, A. Chen, 2011, European journal of cancer.

Methoxychalcone inhibitors of androgen receptor translocation and function.

L. Neckers, J. Trepel, Sunmin Lee, 2012, Bioorganic & medicinal chemistry letters.

The Use of Histone Deacetylase Inhibitors for the Treatment of Solid Tumors

J. Trepel, S. Kummar, E. Donovan, 2007 .

Synthesis and structure-activity relationship studies of novel dihydropyridones as androgen receptor modulators.

L. Neckers, J. Trepel, Min-Jung Lee, 2013, Journal of medicinal chemistry.

The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels.

Vladimir Valera Romero, W Marston Linehan, B. Viollet, 2011, Cancer cell.

Casein kinase 2 phosphorylation of Hsp90 threonine 22 modulates chaperone function and drug sensitivity

L. Neckers, J. Trepel, M. Mollapour, 2011, Oncotarget.

Inhibition of Tumor Cell Motility by the Interferon-inducible GTPase MxA*

W. Linehan, P. Nguyen, J. Trepel, 2009, Journal of Biological Chemistry.

Histone deacetylase inhibitors in cancer therapy

G. Giaccone, J. Trepel, S. Kummar, 2008, Current opinion in oncology.

Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.

S. Steinberg, H. Parnes, J. Trepel, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment.

A. Tesei, N. Zaffaroni, J. Trepel, 2017, Journal of medicinal chemistry.

A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas

G. Giaccone, W. Zein, B. Houk, 2011, Clinical Cancer Research.

Cell microarray platform for anticancer drug development

E. Sausville, W. Telford, S. Hewitt, 2007 .

Pharmacodynamic assessment of histone deacetylase inhibitors: infrared vibrational spectroscopic imaging of protein acetylation.

S. Hewitt, I. W. Levin, J. Trepel, 2008, Analytical chemistry.

Tumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy.

G. Giaccone, L. Neckers, Y. Kim, 2012, Current molecular medicine.

Update on Hsp90 inhibitors in clinical trial.

G. Giaccone, L. Neckers, J. Trepel, 2009, Current topics in medicinal chemistry.

The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels.

R. Sougrat, W. Linehan, R. Srinivasan, 2011, Cancer cell.

Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer.

L. Neckers, J. Trepel, J. Gestwicki, 2018, Cancer research.

1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment.

A. Tesei, N. Zaffaroni, J. Trepel, 2017, Journal of medicinal chemistry.